{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:39:16Z","timestamp":1792067956468,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005933","name":"Camurus AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005933","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.dadr.2025.100329","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T18:43:16Z","timestamp":1744051396000},"page":"100329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series"],"prefix":"10.1016","volume":"15","author":[{"given":"Victoria","family":"Hayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llewellyn","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaye","family":"Byron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Stubley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin T.","family":"Trevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Somogyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshman","family":"Sahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dadr.2025.100329_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","article-title":"Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study","volume":"34","author":"Albayaty","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.dadr.2025.100329_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-2-1","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. life Outcomes"},{"issue":"10","key":"10.1016\/j.dadr.2025.100329_bib3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s40262-023-01288-6","article-title":"Population pharmacokinetic analysis supports initiation treatment and bridging from sublingual buprenorphine to subcutaneous administration of a buprenorphine depot (CAM2038) in the treatment of opioid use disorder","volume":"62","author":"Bj\u00f6rnsson","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.dadr.2025.100329_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0376-8716(03)00071-1","article-title":"Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions","volume":"71","author":"Breen","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.dadr.2025.100329_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: an R package for bayesian multilevel models using stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J. Stat. Softw."},{"issue":"3","key":"10.1016\/j.dadr.2025.100329_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.jcp.0000162804.38829.97","article-title":"Efficacy of buspirone in the treatment of opioid withdrawal","volume":"25","author":"Buydens-Branchey","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.dadr.2025.100329_bib7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"Initial adult health item banks and first wave testing of the patient-reported outcomes measurement information system (PROMIS\u2122) network: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.dadr.2025.100329_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104002","article-title":"I just thought that was the best thing for me to do at this point\u2019: exploring patient experiences with depot buprenorphine and their motivations to discontinue","volume":"115","author":"Clay","year":"2023","journal-title":"Int. J. Drug Policy"},{"issue":"4","key":"10.1016\/j.dadr.2025.100329_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ajad.13024","article-title":"Transition of patients with opioid use disorder from buprenorphine to extended-release naltrexone: a randomized clinical trial assessing two transition regimens","volume":"29","author":"Comer","year":"2020","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.dadr.2025.100329_bib10","unstructured":"R. Core Team, 2016. R: A language and environment for statistical computing. R Foundation for Statistical Computing."},{"key":"10.1016\/j.dadr.2025.100329_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jsat.2015.01.004","article-title":"Naltrexone-Facilitated Buprenorphine Discontinuation: A Feasibility Trial","volume":"53","author":"Dakwar","year":"2015","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2025.100329_bib12","series-title":"Subjective Opioid Withdrawal Scale (SOWS): description, strengths, and knowledge gaps","author":"Fischer","year":"2021"},{"key":"10.1016\/j.dadr.2025.100329_bib13","doi-asserted-by":"crossref","unstructured":"Gowing, L., Ali, R., White, J.M., Mbewe, D., 2017. Buprenorphine for managing opioid withdrawal. Cochrane Database of Systematic Reviews(2).","DOI":"10.1002\/14651858.CD002025.pub5"},{"issue":"10173","key":"10.1016\/j.dadr.2025.100329_bib14","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet (Br. Ed. )"},{"issue":"3","key":"10.1016\/j.dadr.2025.100329_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"4","key":"10.1016\/j.dadr.2025.100329_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40262-020-00957-0","article-title":"Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase ii and phase III trials","volume":"60","author":"Jones","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.dadr.2025.100329_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109464","article-title":"The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001\u20132018: Findings from the OATS retrospective linkage study","volume":"236","author":"Jones","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"10","key":"10.1016\/j.dadr.2025.100329_bib18","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study","volume":"2","author":"Kimber","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.dadr.2025.100329_bib19","author":"Kruschke","year":"2014","journal-title":"Doing Bayesian Data Anal.: A Tutor. R., JAGS, Stan"},{"issue":"2","key":"10.1016\/j.dadr.2025.100329_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1753-6405.2001.tb01832.x","article-title":"Withdrawal from methadone maintenance treatment: prognosis and participant perspectives","volume":"25","author":"Lenn\u00e9","year":"2001","journal-title":"Aust. N. Z. J. Public Health"},{"key":"10.1016\/j.dadr.2025.100329_bib21","unstructured":"Lenth, R.V., 2020. emmeans: Estimated Marginal Means, aka Least-Squares Means. R package Version 1-5-3."},{"issue":"6","key":"10.1016\/j.dadr.2025.100329_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5694\/mja2.52250","article-title":"The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019\u20132022: longitudinal sales data analysis","volume":"220","author":"Lintzeris","year":"2024","journal-title":"Med. J. Aust."},{"issue":"12","key":"10.1016\/j.dadr.2025.100329_bib23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40263-013-0111-9","article-title":"Scopolamine detoxification technique for heroin dependence: a randomized trial","volume":"27","author":"Liu","year":"2013","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.dadr.2025.100329_bib24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.dadr.2025.100329_bib25","series-title":"Manual for the depression anxiety stress scales","author":"Lovibond","year":"1995"},{"key":"10.1016\/j.dadr.2025.100329_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102311","article-title":"Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial","volume":"66","author":"Marsden","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.dadr.2025.100329_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.10.002","article-title":"Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients","volume":"145","author":"McHugh","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.dadr.2025.100329_bib28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/1097-4679(198709)43:5<528::AID-JCLP2270430517>3.0.CO;2-2","article-title":"Assessing pathological detoxification Fear among methadone maintenance patients: The DFSS","volume":"43","author":"Milby","year":"1987","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.dadr.2025.100329_bib29","unstructured":"Musolino, S., Wong, A., Somogyi, A., 2022. A validated UHPLC-MS\/MS assay for quantification of opioids used for cancer pain, APSA-ASCEPT Annual Scientific Meeting. Perth, Australia."},{"issue":"3","key":"10.1016\/j.dadr.2025.100329_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40744-019-00168-5","article-title":"Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA","volume":"6","author":"Radawski","year":"2019","journal-title":"Rheumatol. Ther."},{"issue":"2","key":"10.1016\/j.dadr.2025.100329_bib31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JCP.0b013e318032ec2a","article-title":"Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?","volume":"27","author":"Reed","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.dadr.2025.100329_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/ADM.0000000000000738","article-title":"Using extended release buprenorphine injection to discontinue sublingual buprenorphine: a case series","volume":"15","author":"Ritvo","year":"2021","journal-title":"J. Addict. Med."},{"issue":"3","key":"10.1016\/j.dadr.2025.100329_bib33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ajad.13414","article-title":"Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended-release buprenorphine","volume":"32","author":"Rodriguez","year":"2023","journal-title":"Am. J. Addict."},{"issue":"3","key":"10.1016\/j.dadr.2025.100329_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2016.9382","article-title":"Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial","volume":"316","author":"Rosenthal","year":"2016","journal-title":"JAMA: J. Am. Med. Assoc."},{"issue":"05","key":"10.1016\/j.dadr.2025.100329_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2002-34115","article-title":"Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone","volume":"35","author":"Seifert","year":"2002","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.dadr.2025.100329_bib36","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1360-0443.2006.01348.x","article-title":"An injection depot formulation of buprenorphine: extended biodelivery and effects","volume":"101","author":"Sigmon","year":"2006","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.dadr.2025.100329_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2003.08.006","article-title":"Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification","volume":"73","author":"Sobel","year":"2004","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.dadr.2025.100329_bib38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jurban\/79.4.571","article-title":"Beliefs about methadone in an inner-city methadone clinic","volume":"79","author":"Stancliff","year":"2002","journal-title":"J. Urban Health"},{"issue":"2","key":"10.1016\/j.dadr.2025.100329_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.dadr.2025.100329_bib40","doi-asserted-by":"crossref","unstructured":"Wickham, H., 2017. Tidyverse: Easily install and load\u2019tidyverse\u2019packages. R package version 1.2.1 1(1).","DOI":"10.32614\/CRAN.package.tidyverse"},{"issue":"6","key":"10.1016\/j.dadr.2025.100329_bib41","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1465-3362.2009.00127.x","article-title":"Why do patients report transferring between methadone and buprenorphine?","volume":"28","author":"Winstock","year":"2009","journal-title":"Drug Alcohol Rev."},{"issue":"1","key":"10.1016\/j.dadr.2025.100329_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugpo.2010.08.001","article-title":"Should I stay or should I go?\u201d Coming off methadone and buprenorphine treatment","volume":"22","author":"Winstock","year":"2011","journal-title":"Int. J. Drug Policy"}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:13:36Z","timestamp":1762647216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724625000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"alternative-id":["S2772724625000125"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100329","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 South Eastern Sydney Local Health District, Kogarah, Australia. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100329"}}